Exane Derivatives’s Takeda Pharmaceutical TAK Stock Holding History

Exane Derivatives’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30	Closed	-$430	–	914
2022 Q1	$430	Buy	+30	New	+$440	﹤0.01%	884
2021 Q4	–	Sell	-30	Closed	-$491	–	966
2021 Q3	$491	Hold	30	–	–	﹤0.01%	941
2021 Q2	$503	Hold	30	–	–	﹤0.01%	941
2021 Q1	$548	Hold	30	–	–	﹤0.01%	790
2020 Q4	$546	Hold	30	–	–	﹤0.01%	735
2020 Q3	$535	Hold	30	–	–	﹤0.01%	672
2020 Q2	$538	Hold	30	–	–	﹤0.01%	608
2020 Q1	$455	Hold	30	–	–	﹤0.01%	611
2019 Q4	$600	Hold	30	–	–	﹤0.01%	600
2019 Q3	$516	Hold	30	–	–	﹤0.01%	581
2019 Q2	$531	Hold	30	–	–	﹤0.01%	595
2019 Q1	$611	Buy	+30	New	+$604	﹤0.01%	531

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Exane Derivatives's TAK Position: Q2 2022 in Review

Exane Derivatives sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 30 shares — an estimated $430 sold.

Exane Derivatives first reported a position in TAK in Q1 2019 and held it in 12 quarters. The position peaked at $611 in Q1 2019. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

Exane Derivatives reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 30 Takeda Pharmaceutical shares in Q2 2022, an estimated $430.
Exane Derivatives first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 12 quarters.
Exane Derivatives's Takeda Pharmaceutical position peaked at $611 in Q1 2019.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.